Caris Life Sciences vs ImCheck Therapeutics
Caris Life Sciences vs ImCheck Therapeutics, compared side by side on 18 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Caris Life Sciences is on 59/100 and ImCheck Therapeutics on 60/100.
Where each one leads
Caris Life Sciences
- agent readiness: 47/100 against 34/100
- domain rating: 63/100 against 37/100
- headcount: 1,659 against 47
- funding raised: $700M against $164M
- LinkedIn following: 77,698 against 11,647
ImCheck Therapeutics
Leads on none of the measures we hold for both companies.
At a glance
| Measure | Caris Life Sciences | ImCheck Therapeutics |
|---|---|---|
| What it is | Caris Life Sciences is a leading innovator in molecular science, offering precision medicine solutions for cancer patients through advanced molecular profiling. | ImCheck Therapeutics is a clinical-stage immuno-oncology company developing novel antibody therapies. |
| Category | Biotech, MedTech, HealthTech, Genomics | Biotech, MedTech, HealthTech, Drug Discovery |
| Sells toBusiness model | B2B | B2B |
| Offering | Services | Biotech |
| Founded | 2008 | 2015 |
| Headquarters | Irving, United States | Marseille, France |
| Status | Active | Active |
Size, funding and growth
| Measure | Caris Life Sciences | ImCheck Therapeutics |
|---|---|---|
| Employees | 1,659 | 47 |
| Total funding | $700M | $164M |
| Latest round | Series D | Not published |
| Valuation | $7.8B | Not published |
| LinkedIn followers | 77,698 | 11,647 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Caris Life Sciences | ImCheck Therapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 59/100 | 60/100 |
| Traction | 60/100 | 57/100 |
| Team | Not published | 70/100 |
| Community | Not published | 15/100 |
| Search visibility | 22/100 | 22/100 |
| Quality | 78/100 | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (47/100) | F (34/100) |
| Domain ratingLink authority, 0-100 | 63/100 | 37/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Caris Life Sciences | ImCheck Therapeutics |
|---|---|---|
| Hosting | Self Managed | Self Managed |
| CMS | WordPress | Not detected |
| Frameworks | Not detected | Jquery, Tailwind CSS, Bootstrap |
| Analytics | Google Tag Manager | Google Analytics 4 |
Caris Life Sciences vs ImCheck Therapeutics: common questions
Which is better, Caris Life Sciences or ImCheck Therapeutics?
On our 0-100 score ImCheck Therapeutics rates higher (60/100 against 59/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 18 data points above: read the rows that match what you are buying for.
How do Caris Life Sciences and ImCheck Therapeutics compare on the numbers?
Caris Life Sciences leads on agent readiness (47/100 against 34/100), domain rating (63/100 against 37/100), headcount (1,659 against 47), funding raised ($700M against $164M), LinkedIn following (77,698 against 11,647).
Read the full Caris Life Sciences review and pricing or the ImCheck Therapeutics review and pricing. You can also browse other Caris Life Sciences alternatives we track.